Balanced News: : Novavax initiates trial of COVID-flu combination vaccine candidate

Novavax Inc. NVAX, +7.28% said Friday that it has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) vaccine candidate, as well as for a stand-alone flu vaccine candidate. The biotechnology company said the trial will evaluate the safety and effectiveness of different formulations of the CIC and flu vaccine candidates in peopled aged 50 through 80. The company said it expects initial results from the Phase 2 trial in mid-year 2023.